论文部分内容阅读
目的通过对包头地区不同临床分期的原发性肝癌患者血清中HMGB1浓度检测,探讨血清中HMGB1浓度与肝癌分期的相关性,以评估血清中HMGB1的浓度是否可以作为原发性肝癌分期的评价指标。方法收集不同分期的原发性肝癌患者血清82份,无肝脏疾病及其他肿瘤的健康对照血清标本15份,以ELISA法定量检测血清标本中的HMGB1的浓度。结果 TNMⅠ、Ⅱ、Ⅲ、Ⅳ期肝癌患者的血清HMGB1浓度分别为(29.1±5.0)ng/ml、(57.7±14.2)ng/ml、(101.6±14.8)ng/ml、(176.0±32.5)ng/ml。不同分期之间HMGB1的血清浓度两两比较差异有统计学意义(P﹤0.01);健康对照血清HMGB1浓度为(7.2±3.3)ng/ml,与肝癌患者的HMGB1血清浓度差异有统计学意义(P﹤0.01)。结论研究结果显示血清中HMGB1浓度与原发性肝癌的临床分期密切相关,有望成为评价原发性肝癌分期的一个十分有效的血清标志物。
Objective To detect the serum HMGB1 concentration in patients with primary liver cancer of different clinical stages in Baotou to investigate the correlation between serum HMGB1 concentration and the staging of hepatocellular carcinoma so as to evaluate whether HMGB1 concentration in serum can be used as the evaluation index of primary liver cancer staging . Methods Serum samples of 82 patients with primary liver cancer at different stages, 15 healthy controls without liver disease and other tumors were collected. The concentrations of HMGB1 in serum were detected by ELISA. Results The serum levels of HMGB1 in TNMⅠ, Ⅱ, Ⅲ and Ⅳ were (29.1 ± 5.0) ng / ml, (57.7 ± 14.2) ng / ml and (101.6 ± 14.8) ng / / ml. The serum HMGB1 levels at different stages were statistically significant (P <0.01). The HMGB1 concentration of healthy controls was (7.2 ± 3.3) ng / ml, which was significantly different from the serum levels of HMGB1 in patients with hepatocellular carcinoma (P < P <0.01). Conclusion The results show that serum HMGB1 concentration is closely related to the clinical stage of primary liver cancer and is expected to become a very effective serum marker for the evaluation of primary liver cancer staging.